The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association
Open accessAbstract
Chronic kidney disease (CKD) is classified into five stages with kidney failure being the most severe stage (stage G5). CKD conveys a high risk for coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. Cardiovascular complications are the most common causes of death in patients with kidney failure (stage G5) who are maintained on regular dialysis treatment. Because of the high death rate attributable to cardiovascular (CV) disease, most patients with progressive CKD die before reaching kidney failure. Classical risk factors implicated in CV disease are involved in the early stages of CKD. In intermediate and late stages, non-traditional risk factors, including iso-osmotic and non-osmotic sodium retention, volume expansion, anaemia, inflammation, malnutrition, sympathetic overactivity, mineral bone disorders, accumulation of a class of endogenous compounds called ‘uremic toxins’, and a variety of hormonal disorders are the main factors that accelerate the progression of CV disease in these patients. Arterial disease in CKD patients is characterized by an almost unique propensity to calcification and vascular stiffness. Left ventricular hypertrophy, a major risk factor for heart failure, occurs early in CKD and reaches a prevalence of 70–80% in patients with kidney failure. Recent clinical trials have shown the potential benefits of hypoxia-inducible factor prolyl hydroxylase inhibitors, especially as an oral agent in CKD patients. Likewise, the value of proactively administered intravenous iron for safely treating anaemia in dialysis patients has been shown. Sodium/glucose cotransporter-2 inhibitors are now fully emerged as a class of drugs that substantially reduces the risk for CV complications in patients who are already being treated with adequate doses of inhibitors of the renin-angiotensin system. Concerted efforts are being made by major scientific societies to advance basic and clinical research on CV disease in patients with CKD, a research area that remains insufficiently explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“156 Three major trials, (i) the Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes, 157 a sub-study of the Empagliflozin, CV outcomes, and mortality in Type 2 diabetes, (ii) the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation, 158 and (iii) the Dapagliflozin…”
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · cited 1×
“Indeed, Empagliflozin in the Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (reduced) 160 and Dapagliflozin in the Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction trial 161 produced a substantial reduction in the risk for CV death in patients with…”
Self-citationDe Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
The Disease Burden Associated With Overweight and Obesity
Must, A. (1999) · JAMA · doi:10.1001/jama.282.16.1523 · Cited by 4,780
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 2×
“Figure 2 Relationship between the eGFR and the risk of all-cause and cardiovascular mortality in the CKD Epi consortium meta-analysis.(7).”
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158765 · Cited by 4,030
The Epidemiologic Transition: A Theory of the Epidemiology of Population Change
OMRAN, A. R. (2005) · The Milbank Quarterly · doi:10.1111/j.1468-0009.2005.00398.x · Cited by 3,823
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationForeman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31694-5 · Cited by 2,994
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationAntlanger, M., Aschauer, S., Kopecky, C., Hecking, M., Kovarik, J. J., Werzowa, J., Mascherbauer, J., Genser, B., Säemann, M. D., & Bonderman, D. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000473868 · Cited by 2,808
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027 · cited 1×
“This bone hormone also functions as a growth factor for the myocardium, and its level is strongly associated with the LV mass index in CKD patients.(67) Two large meta-analyses showed that FGF23 is a powerful predictor of the risk of death and cardiovascular (CV) disease in CKD patients(68) and in kidney failure patie…”
Fouque, D., Kalantar-Zadeh, K., Kopple, J., Cano, N., Chauveau, P., Cuppari, L., Franch, H., Guarnieri, G., Ikizler, T. A., Kaysen, G., et al. (2008) · Kidney International · doi:10.1038/sj.ki.5002585 · Cited by 2,000
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citationKeith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., & Smith, D. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.659 · Cited by 1,684
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Largely driven by albuminuria reduction, GLP1RA, irrespective of structural variants, reduced the risk for all-cause mortality, hospital admission for HF and worsening kidney function in patients with Type 2 diabetes with no increased risk of severe hypoglycaemia, retinopathy, or pancreatic adverse effects.(162)”
Levin, A., Bakris, G. L., Molitch, M., Smulders, M., Tian, J., Williams, L. A., & Andress, D. L. (2007) · Kidney International · doi:10.1038/sj.ki.5002009 · Cited by 1,513
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Xie, Y., Bowe, B., Mokdad, A. H., Xian, H., Yan, Y., Li, T., Maddukuri, G., Tsai, C.-Y., Floyd, T., & Al-Aly, Z. (2018) · Kidney International · doi:10.1016/j.kint.2018.04.011 · Cited by 1,391
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Isakova, T., on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group, Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., Appleby, D., Nessel, L., Bellovich, K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.47 · Cited by 1,266
GANESH, S. K., STACK, A. G., LEVIN, N. W., HULBERT-SHEARON, T., & PORT, F. K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102131 · Cited by 1,204
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132 · cited 1×
“Increased sympathetic activity does not regress after renal transplantation(48) but is abolished after bilateral nephrectomy.(28) The causes of sympathetic overactivity in CKD and in kidney failure patients are multiple and include enhanced central sympathetic drive activated by afferent renal nerves in diseased kidne…”
Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences
Kalantar-Zadeh, K., Ikizler, T. A., Block, G., Avram, M. M., & Kopple, J. D. (2003) · American Journal of Kidney Diseases · doi:10.1016/j.ajkd.2003.07.016 · Cited by 1,040
Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
The EVOLVE Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205624 · Cited by 971
Machnik, A., Neuhofer, W., Jantsch, J., Dahlmann, A., Tammela, T., Machura, K., Park, J.-K., Beck, F.-X., Müller, D. N., Derer, W., et al. (2009) · Nature Medicine · doi:10.1038/nm.1960 · Cited by 963
Normal and Pathologic Concentrations of Uremic Toxins
Duranton, F., Cohen, G., De Smet, R., Rodriguez, M., Jankowski, J., Vanholder, R., & Argiles, A. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011121175 · Cited by 961
Self-citationJager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019) · Kidney International · doi:10.1016/j.kint.2019.07.012 · Cited by 957
Self-citationSrour, B., Fezeu, L. K., Kesse-Guyot, E., Allès, B., Méjean, C., Andrianasolo, R. M., Chazelas, E., Deschasaux, M., Hercberg, S., Galan, P., et al. (2019) · BMJ · doi:10.1136/bmj.l1451 · Cited by 955
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904 · cited 1×
“Randomized trials testing monoclonal antibodies targeting IL1β and IL-6 documented the relevance of these cytokines in atherosclerosis(39) and other conditions.(40) The gut microbiota is a key inducer of metabolic inflammation in obesity and Type 2 diabetes(41) as well as in CKD.”
Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Self-citationThe global burden of chronic kidney disease
Cockwell, P., & Fisher, L.-A. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32977-0 · Cited by 857
Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
Levin, A., Thompson, C. R., Ethier, J., Carlisle, E. J. F., Tobe, S., Mendelssohn, D., Burgess, E., Jindal, K., Barrett, B., Singer, J., et al. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70118-6 · Cited by 841
The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90130-4 · Cited by 769
Ridker, P. M., Devalaraja, M., Baeres, F. M. M., Engelmann, M. D. M., Hovingh, G. K., Ivkovic, M., Lo, L., Kling, D., Pergola, P., Raj, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00520-1 · Cited by 737
The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate: A Systematic Review
Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V., & Glorieux, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101062 · Cited by 683
Self-citationGut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes
Scheithauer, T. P. M., Rampanelli, E., Nieuwdorp, M., Vallance, B. A., Verchere, C. B., van Raalte, D. H., & Herrema, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571731 · Cited by 673
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Lash, J. P., Go, A. S., Appel, L. J., He, J., Ojo, A., Rahman, M., Townsend, R. R., Xie, D., Cifelli, D., Cohan, J., et al. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00070109 · Cited by 619 · cited 1×
“Furthermore, CKD and albuminuria are associated with an increased risk of peripheral vascular disease and aortic aneurysms across all stages 14 and progressively higher levels of albuminuria.”
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
Hematocrit Level and Associated Mortality in Hemodialysis Patients
MA, J. Z., EBBEN, J., XIA, H., & COLLINS, A. J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103610 · Cited by 577
Felker, G. M., Anstrom, K. J., Adams, K. F., Ezekowitz, J. A., Fiuzat, M., Houston-Miller, N., Januzzi, J. L., Mark, D. B., Piña, I. L., Passmore, G., et al. (2017) · JAMA · doi:10.1001/jama.2017.10565 · Cited by 548
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
Vaziri, N. D. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00099.2005 · Cited by 538
Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519 · cited 2×
“The results of this trial are in line with the knowledge that high sympathetic activity underlies a high risk for CV events in the haemodialysis population.(54)”
Self-citationIntravenous Iron in Patients Undergoing Maintenance Hemodialysis
Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., McMurray, J. J. V., Murray, H., Tomson, C. R. V., Wheeler, D. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1810742 · Cited by 502
Sympathetic Nerve Activity in End-Stage Renal Disease
Hausberg, M., Kosch, M., Harmelink, P., Barenbrock, M., Hohage, H., Kisters, K., Dietl, K. H., & Rahn, K. H. (2002) · Circulation · doi:10.1161/01.cir.0000034043.16664.96 · Cited by 493
Perrone, A., Giovino, A., Benny, J., & Martinelli, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3818196 · Cited by 459
Zoccali, C., Vanholder, R., Massy, Z. A., Ortiz, A., Sarafidis, P., Dekker, F. W., Fliser, D., Fouque, D., Heine, G. H., Jager, K. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.52 · Cited by 444
Self-citationChronic inflammation in end-stage renal disease and dialysis
Cobo, G., Lindholm, B., & Stenvinkel, P. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy175 · Cited by 439
Proinflammatory Cytokines Lowering Erythropoietin Production
JELKMANN, W. (1998) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1998.18.555 · Cited by 422 · cited 1×
“It also weakens the stimulatory activity of erythropoietin on erythrocyte generation.(93) Inflammation engenders sarcopenia and malnutrition in CKD patients and induces a peculiar condition referred to as the malnutrition/protein energy wasting (PEW) syndrome,(94) which manifests as fatigue, nausea, lack of appetite,…”
Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial
Manfredini, F., Mallamaci, F., D’Arrigo, G., Baggetta, R., Bolignano, D., Torino, C., Lamberti, N., Bertoli, S., Ciurlino, D., Rocca-Rey, L., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030378 · Cited by 420
Self-citationChronic Fluid Overload and Mortality in ESRD
Zoccali, C., Moissl, U., Chazot, C., Mallamaci, F., Tripepi, G., Arkossy, O., Wabel, P., & Stuard, S. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121341 · Cited by 410
Self-citationReduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure
Ligtenberg, G., Blankestijn, P. J., Oey, P. L., Klein, I. H. H., Dijkhorst-Oei, L.-T., Boomsma, F., Wieneke, G. H., van Huffelen, A. C., & Koomans, H. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401704 · Cited by 409
AKI and Long-Term Risk for Cardiovascular Events and Mortality
Odutayo, A., Wong, C. X., Farkouh, M., Altman, D. G., Hopewell, S., Emdin, C. A., & Hunn, B. H. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010105 · Cited by 391
(2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.001 · Cited by 363
Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy?
Oliveira, R. B., Cancela, A. L. E., Graciolli, F. G., Dos Reis, L. M., Draibe, S. A., Cuppari, L., Carvalho, A. B., Jorgetti, V., Canziani, M. E., & Moysés, R. M. A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05420709 · Cited by 357
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338
Physical Activity and Mortality in Chronic Kidney Disease (NHANES III)
Beddhu, S., Baird, B. C., Zitterkoph, J., Neilson, J., & Greene, T. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01970309 · Cited by 331
Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure
Grassi, G., Quarti-Trevano, F., Seravalle, G., Arenare, F., Volpe, M., Furiani, S., Dell'Oro, R., & Mancia, G. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.164780 · Cited by 311
Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis
Masson, P., Webster, A. C., Hong, M., Turner, R., Lindley, R. I., & Craig, J. C. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv009 · Cited by 308
Ridker, P. M., MacFadyen, J. G., Glynn, R. J., Koenig, W., Libby, P., Everett, B. M., Lefkowitz, M., Thuren, T., & Cornel, J. H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.490 · Cited by 297
Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018
Fishbane, S., & Spinowitz, B. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.09.026 · Cited by 293
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease
Agarwal, R., Sinha, A. D., Cramer, A. E., Balmes-Fenwick, M., Dickinson, J. H., Ouyang, F., & Tu, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110730 · Cited by 292
Self-citationEndothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update
Roumeliotis, S., Mallamaci, F., & Zoccali, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082359 · Cited by 284
Self-citationAssociation of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD
Kovesdy, C. P., Anderson, J. E., & Kalantar-Zadeh, K. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn633 · Cited by 277
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Self-citationVascular calcification in chronic kidney disease: different bricks in the wall?
Vervloet, M., & Cozzolino, M. (2017) · Kidney International · doi:10.1016/j.kint.2016.09.024 · Cited by 265
Drechsler, C., Pilz, S., Obermayer-Pietsch, B., Verduijn, M., Tomaschitz, A., Krane, V., Espe, K., Dekker, F., Brandenburg, V., Marz, W., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq246 · Cited by 258
Self-citationEpidemiology of Acute Infections among Patients with Chronic Kidney Disease
Dalrymple, L. S., & Go, A. S. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01290308 · Cited by 254
Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
Chertow, G. M., Pergola, P. E., Farag, Y. M. K., Agarwal, R., Arnold, S., Bako, G., Block, G. A., Burke, S., Castillo, F. P., Jardine, A. G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035938 · Cited by 254
Self-citationDaprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
Singh, A. K., Carroll, K., Perkovic, V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113379 · Cited by 247
Self-citationDaprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
Singh, A. K., Carroll, K., McMurray, J. J. V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113380 · Cited by 233
Self-citationSodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease
Mills, K. T., Chen, J., Yang, W., Appel, L. J., Kusek, J. W., Alper, A., Delafontaine, P., Keane, M. G., Mohler, E., Ojo, A., et al. (2016) · JAMA · doi:10.1001/jama.2016.4447 · Cited by 232
Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., & Tegegne, G. G. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft515 · Cited by 232
Self-citationEustace, J. A., Astor, B., Muntner, P. M., Ikizler, T. A., & Coresh, J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00481.x · Cited by 230
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P., Ferro, C. J., Halimi, J.-M., Heine, G. H., Jadoul, M., Jarraya, F., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw433 · Cited by 229
Self-citationStenvinkel, P., Wanner, C., Metzger, T., Heimbürger, O., Mallamaci, F., Tripepi, G., Malatino, L., & Zoccali, C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00637.x · Cited by 214
Self-citationEfficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial
Charytan, D. M., Sabatine, M. S., Pedersen, T. R., Im, K., Park, J.-G., Pineda, A. L., Wasserman, S. M., Deedwania, P., Olsson, A. G., Sever, P. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.513 · Cited by 210 · cited 18×
“Inappropriately low synthesis of erythropoietin by failing kidneys, accumulation of uremic toxins, iron deficiency, and inflammation all participate in the pathogenesis of anaemia in patients with CKD. 55 59 By increasing cardiac workload to compensate for reduced oxygen delivery to peripheral tissues, anaemia leads t…”
InfluentialGuedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208
Komaba, H., Taniguchi, M., Wada, A., Iseki, K., Tsubakihara, Y., & Fukagawa, M. (2015) · Kidney International · doi:10.1038/ki.2015.72 · Cited by 196
Wolf, M., & White, K. E. (2014) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000447020.74593.6f · Cited by 196
Assessment and Management of Hypertension in Patients on Dialysis
Agarwal, R., Flynn, J., Pogue, V., Rahman, M., Reisin, E., & Weir, M. R. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060601 · Cited by 190
Self-citationKelly, D., Ademi, Z., Doehner, W., Lip, G. Y. H., Mark, P. B., Toyoda, Ḱ., Wong, C. X. J., Sarnak, M. J., Cheung, M., Herzog, C. A., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.029680 · Cited by 190
Self-citationPlasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients
Liabeuf, S., Lenglet, A., Desjardins, L., Neirynck, N., Glorieux, G., Lemke, H.-D., Vanholder, R., Diouf, M., Choukroun, G., & Massy, Z. A. (2012) · Kidney International · doi:10.1038/ki.2012.301 · Cited by 180
Self-citationSerum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease
Navaneethan, S. D., Schold, J. D., Arrigain, S., Jolly, S. E., Wehbe, E., Raina, R., Simon, J. F., Srinivas, T. R., Jain, A., Schreiber, M. J., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03730411 · Cited by 180
Influence of nephrectomy on tumor necrosis factor clearance in a murine model
Bemelmans, M. H., Gouma, D. J., & Buurman, W. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.5.2007 · Cited by 179
Exploring metabolic dysfunction in chronic kidney disease
Slee, A. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-36 · Cited by 179
Smith, D. H., Thorp, M. L., Gurwitz, J. H., McManus, D. D., Goldberg, R. J., Allen, L. A., Hsu, G., Sung, S. H., Magid, D. J., & Go, A. S. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000221 · Cited by 169
Tsai, Y.-C., Chiu, Y.-W., Tsai, J.-C., Kuo, H.-T., Hung, C.-C., Hwang, S.-J., Chen, T.-H., Kuo, M.-C., & Chen, H.-C. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03610414 · Cited by 167
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167
Arterial stiffness in chronic kidney disease: causes and consequences
Chue, C. D., Townend, J. N., Steeds, R. P., & Ferro, C. J. (2010) · Heart · doi:10.1136/hrt.2009.184879 · Cited by 165
Self-citationHimmelfarb, J. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17605.x · Cited by 158
MacKinnon, H. J., Wilkinson, T. J., Clarke, A. L., Gould, D. W., O’Sullivan, T. F., Xenophontos, S., Watson, E. L., Singh, S., & Smith, A. C. (2018) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622318785575 · Cited by 158
Li, H., Lu, W., Wang, A., Jiang, H., & Lyu, J. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13355 · Cited by 156
Koiwa, F., Kazama, J. J., Tokumoto, A., Onoda, N., Kato, H., Okada, T., Nii‐Kono, T., Fukagawa, M., & Shigematsu, T. (2005) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2005.00293.x · Cited by 147
Adipose tissue is a regulated source of interleukin-10
Juge-Aubry, C. E., Somm, E., Pernin, A., Alizadeh, N., Giusti, V., Dayer, J.-M., & Meier, C. A. (2005) · Cytokine · doi:10.1016/j.cyto.2004.10.017 · Cited by 144
Drug adherence in chronic kidney diseases and dialysis
Burnier, M., Pruijm, M. T., Wuerzner, G., & Santschi, V. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu015 · Cited by 144
Self-citationRegulation and Effects of FGF23 in Chronic Kidney Disease
Musgrove, J., & Wolf, M. S. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034650 · Cited by 141
Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease
Zoccali, C., Mallamaci, F., Tripepi, G. L., Parlongo, S., Cutrupi, S., Benedetto, F. A., Cataliotti, A., & Malatino, L. (2002) · Hypertension · doi:10.1161/01.hyp.0000022063.50739.60 · Cited by 136
Self-citationNicola, L. D., Minutolo, R., Chiodini, P., Zoccali, C., Castellino, P., Donadio, C., Strippoli, M., Casino, F. G., Giannattasio, M., Petrarulo, F., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000085 · Cited by 135
Self-citationComparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients
Brookhart, M. A., Schneeweiss, S., Avorn, J., Bradbury, B. D., Liu, J., & Winkelmayer, W. C. (2010) · JAMA · doi:10.1001/jama.2010.206 · Cited by 132
Kreiner, F. F., Kraaijenhof, J. M., von Herrath, M., Hovingh, G. K., & von Scholten, B. J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2045952 · Cited by 129
Russo, D., Corrao, S., Battaglia, Y., Andreucci, M., Caiazza, A., Carlomagno, A., Lamberti, M., Pezone, N., Pota, A., Russo, L., et al. (2011) · Kidney International · doi:10.1038/ki.2011.69 · Cited by 126
Cause-Specific Deaths in Non–Dialysis-Dependent CKD
Navaneethan, S. D., Schold, J. D., Arrigain, S., Jolly, S. E., & Nally, J. V. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101034 · Cited by 125
Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K. B., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003212 · Cited by 125
Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients
London, G. M., de Vernejoul, M. C., Fabiani, F., Marchais, S. J., Guérin, A. P., Métivier, F., London, A. M., & Llach, F. (1987) · Kidney International · doi:10.1038/ki.1987.293 · Cited by 123
Garimella, P. S., Hart, P. D., O’Hare, A. M., DeLoach, S. S., Herzog, C. A., & Hirsch, A. T. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.02.340 · Cited by 123
Robinson, B. M., Joffe, M. M., Berns, J. S., Pisoni, R. L., Port, F. K., & Feldman, H. I. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00693.x · Cited by 121
Fischer, M. J., Go, A. S., Lora, C. M., Ackerson, L., Cohan, J., Kusek, J. W., Mercado, A., OJO, A. O., Ricardo, A. C., Rosen, L., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.05.010 · Cited by 120
Sodium Restriction in Patients With CKD: A Randomized Controlled Trial of Self-management Support
Meuleman, Y., Hoekstra, T., Dekker, F. W., Navis, G. J., Vogt, L., van der Boog, P. J. M., Bos, W. J. W., van Montfrans, G. A., van Dijk, S., van Dijk, S., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.08.042 · Cited by 118
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
Ridker, P. M., Tuttle, K. R., Perkovic, V., Libby, P., & MacFadyen, J. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac444 · Cited by 117
Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism
Costa‐Hong, V., Jorgetti, V., Gowdak, L. H. W., Moysés, R. M. A., Krieger, E. M., & Lima, J. J. G. D. (2007) · Surgery · doi:10.1016/j.surg.2007.06.015 · Cited by 109
Chronic Kidney Disease and Arterial Stiffness: A Two-Way Path
Inserra, F., Forcada, P. J., Castellaro, A., & Castellaro, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765924 · Cited by 108
Serum bicarbonate and mortality in adults in NHANES III
Raphael, K. L., Zhang, Y., Wei, G., Greene, T., Cheung, A. K., & Beddhu, S. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs609 · Cited by 105
Self-reported Medication Adherence and CKD Progression
Cedillo-Couvert, E. A., Ricardo, A. C., Chen, J., Cohan, J., Fischer, M. J., Krousel-Wood, M. A., Kusek, J. W., Lederer, S., Lustigova, E., OJO, A. O., et al. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.01.007 · Cited by 101
Dialysis-Induced Cardiovascular and Multiorgan Morbidity
Canaud, B., Kooman, J. P., Selby, N. M., Taal, M. W., Francis, S., Maierhofer, A. P., Kopperschmidt, P., Collins, A., & Kotanko, P. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.08.031 · Cited by 94
Self-citationSarnak, M. J., Poindexter, A. E., Wang, S.-R., Beck, G. J., Kusek, J. W., Marcovina, S. M., Greene, T., & Levey, A. S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00677.x · Cited by 93
Awan, A. A., Walther, C. P., Richardson, P., Shah, M., Winkelmayer, W. C., & Navaneethan, S. D. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz192 · Cited by 93
Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle
Khan, Y. H., Sarriff, A., Adnan, A. S., Khan, A. H., & Mallhi, T. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159335 · Cited by 91
Nakamura, T., Kawagoe, Y., Matsuda, T., Ueda, Y., Shimada, N., Ebihara, I., & Koide, H. (2004) · Kidney & Blood Pressure Research · doi:10.1159/000077536 · Cited by 90
Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease
Jazani, N. H., Savoj, J., Lustgarten, M. S., Lau, W. L., & Vaziri, N. D. (2019) · Diseases · doi:10.3390/diseases7010021 · Cited by 90
Avesani, C. M., Draibe, S. A., Kamimura, M. A., Colugnati, F. A. B., & Cuppari, L. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.08.023 · Cited by 84
Intradialytic Hypoxemia and Clinical Outcomes in Patients on Hemodialysis
Meyring-Wösten, A., Zhang, H., Ye, X., Fuertinger, D. H., Chan, L., Kappel, F., Artemyev, M., Ginsberg, N., Wang, Y., Thijssen, S., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08510815 · Cited by 84
Self-citationLiu, Y., Ma, X., Zheng, J., Jia, J., & Yan, T. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0605-7 · Cited by 83
Kang, H., Zhang, J., Zhang, X., Qin, G., Wang, K., Deng, Z., Fang, Y., & Chen, G. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173444 · Cited by 83
Martins, P., Marques, E. A., Leal, D. V., Ferreira, A., Wilund, K. R., & Viana, J. L. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02407-w · Cited by 81
Obesity and kidney disease: hidden consequences of the epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., Li, P. K., García-García, G., Benghanem-Gharbi, M., Bollaert, R., Dupuis, S., Erk, T., Kalantar‐Zadeh, K., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.10.019 · Cited by 73
Self-citationRisk Assessment for Sudden Cardiac Death in Dialysis Patients
Saravanan, P., & Davidson, N. C. (2010) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.110.937888 · Cited by 72
Lishmanov, A., Dorairajan, S., Pak, Y., Chaudhary, K. R., & Chockalingam, A. (2011) · International Urology and Nephrology · doi:10.1007/s11255-010-9897-2 · Cited by 69
Chronic kidney disease measures and the risk of abdominal aortic aneurysm
Matsushita, K., Kwak, L., Ballew, S. H., Grams, M. E., Selvin, E., Folsom, A. R., Coresh, J., & Tang, W. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.043 · Cited by 65
Badve, S. V., Palmer, S. C., Strippoli, G. F., Roberts, M. A., Teixeira-Pinto, A. M., Boudville, N. C., Cass, A., Hawley, C. M., Hiremath, S. S., Pascoe, E. M., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.03.418 · Cited by 64
Tai, R., Ohashi, Y., Mizuiri, S., Aikawa, A., & Sakai, K. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-189 · Cited by 63
Dasgupta, I., & Zoccali, C. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18434 · Cited by 63
Self-citationTesfaye, W. H., Erku, D., Mekonnen, A. B., Tefera, Y. G., Castelino, R. L., Sud, K., Thomas, J., & Obamiro, K. O. (2021) · Journal of Nephrology · doi:10.1007/s40620-020-00895-x · Cited by 61
Pisano, A., Bolignano, D., Mallamaci, F., D’Arrigo, G., Halimi, J., Persu, A., Wuerzner, G., Sarafidis, P. A., Watschinger, B., Burnier, M., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz092 · Cited by 59
Self-citationPark, J., Campese, V. M., Nobakht, N., & Middlekauff, H. R. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.90849.2008 · Cited by 55
Qirjazi, E., Salerno, F. R., Akbari, A., Hur, L., Penny, J. D., Scholl, T. J., & McIntyre, C. W. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa036 · Cited by 54
Level of Albuminuria and Risk of Stroke: Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Chang, K., & Ovbiagele, B. I. (2010) · Cerebrovascular Diseases · doi:10.1159/000317069 · Cited by 53
Phosphate binders in chronic kidney disease: an updated narrative review of recent data
Floege, J. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00689-w · Cited by 50
Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis
Dörr, K., Kammer, M., Reindl‐Schwaighofer, R., Lorenz, M., Prikoszovich, T., Marculescu, R., Beitzke, D., Wielandner, A., Erben, R. G., & Oberbauer, R. W. (2021) · Circulation Research · doi:10.1161/circresaha.120.318556 · Cited by 50
Mallamaci, F., D’Arrigo, G., Tripepi, G. L., Lamberti, N., Torino, C., Manfredini, F., & Zoccali, C. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03160322 · Cited by 46
Self-citationDietary interventions for mineral and bone disorder in people with chronic kidney disease
Liu, Z., Su, G., Guo, X., Wu, Y., Liu, X., Zou, C., Zhang, L., Yang, Q., Xu, Y., & Ma, W. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010350.pub2 · Cited by 44
Bashir, A. M., Moody, W. E., Edwards, N. C., Ferro, C. J., Townend, J., & Steeds, R. P. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.01.012 · Cited by 44
Self-citationLi, W.-J., Chen, X., Nie, X., Zhang, J., Cheng, Y., Lin, X., & Wu, S. (2015) · Clinics · doi:10.6061/clinics/2015(04)14 · Cited by 42
Koppe, L., & Soulage, C. O. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.025 · Cited by 42
Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease
Fernández-Prado, R., Pérez-Gómez, M. V., & Ortíz, A. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa001 · Cited by 40
Xue, C., Yang, B., Zhou, C., Dai, B., Liu, Y., Mao, Z., Yu, S., & Mei, C. (2016) · American Journal of Nephrology · doi:10.1159/000454959 · Cited by 38
Siddiqi, L., Prakken, N. H. J., Velthuis, B. K., Cramer, M. J., Oey, P. L., de Boer, P., Bots, M. L., & Blankestijn, P. J. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq175 · Cited by 37
Metabolic Acidosis and Cardiovascular Disease in CKD
Collister, D., Ferguson, T. W., Funk, S. E., Reaven, N. L., Mathur, V. S., & Tangri, N. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.04.011 · Cited by 35
Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine
Hausberg, M., Lang, D., Levers, A., Suwelack, B. M., Kisters, K., Tokmak, F., Barenbrock, M., & Kosch, M. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000222767.15100.e4 · Cited by 33
Verdalles, Ú., de Vinuesa, S. G., Goicoechea, M., Quiroga, B., Reque, J., Panizo, N., Arroyo, D., & Luño, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs420 · Cited by 28
Ye, J., Dai, Y., Mao, H., Zheng, W., & Zhang, J. (2021) · Nitric Oxide · doi:10.1016/j.niox.2021.03.002 · Cited by 25
The European Kidney Health Alliance (EKHA) and the Decade of the KidneyTM
Vanholder, R. C., Conway, P. T., Gallego, D., Scheres, E., & Wieringa, F. P. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac211 · Cited by 20
Self-citationSleep Apnea as a Cardiorenal Risk Factor in CKD and Renal Transplant Patients
Zoccali, C., Roumeliotis, S. K., & Mallamaci, F. (2021) · Blood Purification · doi:10.1159/000513424 · Cited by 19
Self-citationMajor pathways of the reno–cardiovascular link: the sympathetic and renin–angiotensin systems
Blankestijn, P. J., London, G. M., Fliser, D., Jager, K. J., Lindholm, B., Goldsmith, D. J. A., Więcek, A., Süleymanlar, G., Agarwal, R., Ortíz, A., et al. (2011) · Kidney International Supplements · doi:10.1038/kisup.2011.3 · Cited by 17
Self-citationKotsis, F., Schultheiß, U. T., Wuttke, M., Schlosser, P., Mielke, J., Becker, M. S., Oefner, P. J., Karoly, E. D., Mohney, R. P., Eckardt, K., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021010063 · Cited by 13
Panuccio, V. A., Mallamaci, F., Pizzini, P., Tripepi, R., Garofalo, C., Parlongo, G., Caridi, G., Provenzano, M., Mafrica, A., Simone, G. D., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa262 · Cited by 10
Self-citationZhang, H., Xiang, S., Dai, Z., & Fan, Y. (2021) · Biomarkers · doi:10.1080/1354750x.2021.1954694 · Cited by 9
Endogenous Mammalian Cardiotonic Steroids—A New Cardiovascular Risk Factor?—A Mini-Review
Słabiak-Błaż, N., & Piecha, G. (2021) · Life · doi:10.3390/life11080727 · Cited by 8
Covic, A. C., Fliser, D., Goldsmith, D. J. A., Lindholm, B., London, G. M., Martinez, A., Süleymanlar, G., Wiecek, A., & Zoccali, C. (2009) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfp121 · Cited by 4
Self-citation
Metadata
- Authors
- Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., Wanner, C., Burnier, M., Vanholder, R., & Wiecek, A.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-05-30
- Volume
- 119
- Issue
- 11
- Pages
- 2017-2032
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W4378745282
- Cited by
- 363
- References
- 174
- FWCI
- 59.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.